Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy

NCT06169930 — Completed, 2957 participants, Yongtao Han

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Development and Validation of A Overall Survival Prediction Model for Esophageal Squamous Cell Carcinoma: A Novel pN Classification

RegistryNCT06169930, acronym OSmodel
StatusCompleted
Study typeObservational
Enrollment2957 (Actual)
SponsorYongtao Han (Other)
ConditionsSurvivorship
InterventionsThis was an observational study without any intervention (Other)
Datesstart 2023-12-01, primary completion 2023-12-01, completion 2023-12-01, first posted 2023-12-14, last updated 2023-12-14
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
All trials for Survivorship All trials of This was an observational study without any intervention

-Summary

In this retrospective study, we analyzed data from the Sichuan Cancer Hospital \& Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables.

Expand all sections  ·  Collapse all

+Detailed description

In this retrospective study, we analyzed data from the Sichuan Cancer Hospital \& Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables. Additionally, the receiver operating characteristic curve demonstrated an area under the curve greater than 0.7 at 1, 3, and 5 years in both the verification and training groups. Furthermore, Kaplan-Meier (K-M) curves showed that our model effectively distinguished between high- and low-risk groups (p < 0.01).

+Arms and interventions

ArmTypeInterventionsDescription
high-riskOther: This was an observational study without any intervention
low-riskOther: This was an observational study without any intervention
  • This was an observational study without any intervention (Other): This was an observational study without any intervention

+Outcome measures

Primary outcomes

  • Survival [April 2022-April 2024]: Overall survival (OS) was defined as the time from the month and year of surgery until death or the last follow-up in April 2022.

+Eligibility

Sex: All, ages: 18 Years to 90 Years

Inclusion criteria:

* Patients underwent esophagectomy at our hospital.

Exclusion criteria:

* pathology confirmed a non-squamous cell carcinoma,
* the tumor was located outside of the thoracic region,
* R1/R2 resection was performed indicating incomplete tumor removal,
* evidence of distant tumor metastasis was observed, or
* they underwent preoperative neoadjuvant therapy

+Locations (1)

FacilityCityCountryStatus
Sichuan Cancer Hospital and Research InstituteChengdu, SichuanChina